Hormones, contraception, pregnancy, and menopause all interact with migraine in important ways. A practical guide for women and the providers who care for them.
About 1 in 5 women and 1 in 16 men experience migraine. The gap emerges at puberty and persists through midlife.
Estrogen fluctuations across the menstrual cycle, during pregnancy, and around menopause are powerful migraine triggers. The trigeminal nerve and pain-processing pathways also respond differently in women.
On average, women with migraine miss more work, have more severe pain, and experience more associated symptoms like nausea.
Migraine attacks that occur in a predictable window around menstruation — typically 2 days before through 3 days into the period.
Up to 70% of women with migraine report menstrual-related attacks. About 7-14% have "pure menstrual migraine" with attacks ONLY during this window.
The natural drop in estrogen that triggers menstruation also affects serotonin and other neurotransmitters involved in migraine.
Often requires longer-acting preventive strategies that cover the full menstrual window — including perimenstrual NSAID protocols or miniprophylaxis with triptans or gepants.
Can worsen migraine with aura, increase stroke risk, and produce more frequent attacks. Should be discussed carefully with a provider, especially in women who have migraine with aura.
Generally safer and often neutral or beneficial for migraine. The hormonal IUD (Mirena, Liletta) is often a good choice for women with menstrual migraine.
Eliminating the hormone-free interval can reduce menstrual migraine by avoiding the estrogen drop. Some providers prescribe this specifically for migraine management.
Up to 70% report fewer attacks, especially in the 2nd and 3rd trimesters. Estrogen levels are high and stable during this time.
Hormonal changes, dehydration, sleep disruption, and stress can all trigger attacks early in pregnancy.
Many migraine medications are not safe in pregnancy. Acetaminophen is the first-line acute treatment. Magnesium, riboflavin, and certain other preventives can be used. Procedures like TEMMA are generally deferred until postpartum.
New severe headache in pregnancy — especially with high blood pressure, vision changes, or upper abdominal pain — needs urgent evaluation for preeclampsia.
Hormonal fluctuations during the transition to menopause are unpredictable. Many women have their worst migraine years in their late 40s.
Once estrogen stabilizes at low levels, menstrual migraine typically resolves. About 60-70% of women report improvement post-menopause.
Can trigger severe migraine worsening if not managed with gradual hormone replacement. Discuss with your provider.
Transdermal estrogen (patch, gel) at the lowest effective dose is generally safer than oral estrogen for migraine. Continuous rather than cyclic use avoids the hormone-free interval.
About 30% of women with migraine experience aura, compared to lower rates in men. Aura with combined hormonal contraception is a particular concern.
About 1.5-2x more common than in men, partly because menstrual and hormonal patterns can push episodic migraine into chronic.
Uncontrolled migraine — especially with aura — is associated with slightly increased risk of preeclampsia, preterm birth, and low birth weight. Good management matters.
Some women find that triptans or NSAIDs work better at certain points in the cycle. Tracking response can help optimize timing.
For women whose migraine is tied to hormonal cycles and is not well-controlled with standard approaches, TEMMA offers a non-hormonal, drug-free option. It targets the underlying migraine pathway — not the hormone cycle.
Learn About TEMMA